| 摘要 |
Monoclonal antibody (MAb) that inhibits factor 7 activating protease (FSAP), or its proenzyme, that activates blood coagulation factor VII (F7), is new. Independent claims are also included for the following: (1) Hybridoma cell lines that produce MAb; (2) Epitope (E) that binds to the antibody (MAb') produced by hybridoma DSM ACC 2533; (3) Monoclonal antibodies that bind to (E); (4) Peptides that competitively inhibit binding of MAb' to FSAP; (5) Single-chain antibodies (SAb) and humanized antibodies that have the binding specificity of MAb'; (6) Stabilized FSAP or its proenzyme, inhibited by addition of MAb; (7) Blood coagulation factor VII (F7) composition that contains MAb; (8) Stabilized factor V, factor VIII or fibrinogen composition that is protected against degradation by FSAP by addition of MAb; (9) Determining activity of FSAP by treating a sample with MAb and then measuring any residual amidolytic activity; (10) Preparing FSAP or its proenzyme, using MAb as immunoadsorbent; and (11) Preparing FSAP in which MAb is added to the starting material from which FSAP is recovered. |
